title: Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants.
abstract: The pharmacokinetics of valganciclovir were studied in 8 infants ranging in age from 4 to 90 days (mean 20 days). We suggest that doses of 15 mg/kg given twice daily may be suitable for neonates and young infants.
authors.affiliation: Departments of Pediatrics, University of Florence, Florence, Italy.
authors.forename: Luisa
authors.initials: L
authors.lastname: Galli
authors.forename: Andrea
authors.initials: A
authors.lastname: Novelli
authors.forename: Elena
authors.initials: E
authors.lastname: Chiappini
authors.forename: Paola
authors.initials: P
authors.lastname: Gervaso
authors.forename: Maria Iris
authors.initials: MI
authors.lastname: Cassetta
authors.forename: Stefania
authors.initials: S
authors.lastname: Fallani
authors.forename: Maurizio
authors.initials: M
authors.lastname: de Martino
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000151:congenital / Q000188:drug therapy* / Q000821:virology; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010865:Pilot Projects; D000077562:Valganciclovir; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D000077562:Valganciclovir; D015774:Ganciclovir